IO103: IO Biotech’s lead anti-cancer therapy targeting PD-L1
IO103 is a anti-cancer therapy containing an XX-mer PD-L1-derived peptide. it is a disruptive immune modulating anti-cancer therapy with dual mode of action killing both cancer and immuno suppressive cells.
IO103 is first-in-class PD-L1 disruptive anti-cancer therapy which potentially can be the ideal safe and effective add-on treatment to checkpoint inhibitors for multiple cancer indications.
Clinical statusCurrently three Investigator Initiated Trials is ongoing with IO103
Pre-clinical and clinical dataIO Biotech has published following preclinical data related to PDL1
In addition, non-published data from phase I study confirms IO103 as safe and well tolerated.